tailieunhanh - A non-controlled, single arm, open label, phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic, inoperable pancreatic cancer: ParvOryx02 protocol

Metastatic pancreatic cancer has a dismal prognosis, with a mean six-month progression-free survival of approximately 50% and a median survival of about 11 months. Despite intensive research, only slight improvements of clinical outcome could be achieved over the last decades. Hence, new and innovative therapeutic strategies are urgently required. | A non-controlled single arm open label phase II study of intravenous and intratumoral administration of ParvOryx in patients with metastatic inoperable pancreatic cancer ParvOryx02 protocol

TÀI LIỆU LIÊN QUAN
TỪ KHÓA LIÊN QUAN